114 related articles for article (PubMed ID: 299219)
1. [Prognostic factors in the drug therapy of metastasizing breast cancer].
Mörz R; Schemper M; Bettelheim P; Breyer S; Francesconi M; Graninger W; Jakesz R; Kolb R; Micksche M; Rainer H; Reiner G; Moser K
Acta Med Austriaca Suppl; 1979; 6():319-22. PubMed ID: 299219
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in metastatic breast cancer treated with combination chemotherapy.
Swenerton KD; Legha SS; Smith T; Hortobagyi GN; Gehan EA; Yap HY; Gutterman JU; Blumenschein GR
Cancer Res; 1979 May; 39(5):1552-62. PubMed ID: 427797
[TBL] [Abstract][Full Text] [Related]
3. [Metastatic breast cancers: comparison of the prognostic significance and the sensitivity to chemotherapy according to the presence of estradiol and progesterone receptors].
Pouillart P; Madgelenat H; Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Polijcak M; Asselain B
Bull Cancer; 1982; 69(5):461-7. PubMed ID: 7165808
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer.
Kiang DT; Frenning DH; Goldman AI; Ascensao VF; Kennedy BJ
N Engl J Med; 1978 Dec; 299(24):1330-4. PubMed ID: 714108
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors affecting response to aminoglutethimide in advanced breast cancer.
Brufman G
Anticancer Res; 1993; 13(4):1235-7. PubMed ID: 8352549
[TBL] [Abstract][Full Text] [Related]
6. Relationship between estrogen-receptor proteins and response to chemotherapy in breast cancer.
Levine RM; Lippman ME
Cancer Treat Rep; 1984 Apr; 68(4):573-6. PubMed ID: 6370427
[No Abstract] [Full Text] [Related]
7. Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations.
Smalley RV; Bartolucci AA
Eur J Cancer (1965); 1980; Suppl 1():141-6. PubMed ID: 7318861
[No Abstract] [Full Text] [Related]
8. [Value of hormone therapy in metastasizing breast cancer].
Samonigg H
Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208
[TBL] [Abstract][Full Text] [Related]
9. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.
Lippman ME; Allegra JC; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC; Warren R
N Engl J Med; 1978 Jun; 298(22):1223-8. PubMed ID: 651963
[TBL] [Abstract][Full Text] [Related]
10. [Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].
Michlmayr G; Kratzer H; Denz H; Huber H
Wien Klin Wochenschr; 1981 Mar; 93(6):205-7. PubMed ID: 7281697
[TBL] [Abstract][Full Text] [Related]
11. [Place of hormone receptor determination in the therapeutic strategy of breast cancer].
Clavel B; Gest J
Pathol Biol (Paris); 1983 Dec; 31(10):809-18. PubMed ID: 6366702
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for breast cancer.
Allegra JC; Lippman ME
Compr Ther; 1979 Feb; 5(2):13-7. PubMed ID: 428200
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
14. Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer.
Mortimer J; Reimer R; Greenstreet R; Groppe C; Bukowski R
Cancer Treat Rep; 1981; 65(9-10):763-6. PubMed ID: 7273011
[TBL] [Abstract][Full Text] [Related]
15. [Cytostatic therapy in metastasizing breast cancer].
Gynning I; Mattsson W
Lakartidningen; 1978 Apr; 75(15):1512-5. PubMed ID: 651418
[No Abstract] [Full Text] [Related]
16. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin in the treatment of advanced breast cancer; comparative studies of three combination chemotherapy regimes.
Brown I; Ward HW
Clin Oncol; 1976 Jun; 2(2):105-11. PubMed ID: 954258
[No Abstract] [Full Text] [Related]
18. Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy.
Nisman B; Barak V; Hubert A; Kaduri L; Lyass O; Baras M; Peretz T
Anticancer Res; 2003; 23(2C):1939-42. PubMed ID: 12820483
[TBL] [Abstract][Full Text] [Related]
19. [Metastatic cancer of the breast treated by polychemotherapy: a new prognostic approach].
Nadal JM; Jouve M; Mosseri V; Asselain B; Pouillart P
Bull Cancer; 1988; 75(8):757-69. PubMed ID: 3179512
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
DiStefano A; Yap HY; Blumenschein GR
Cancer Treat Rep; 1981; 65(1-2):33-8. PubMed ID: 7013977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
